irhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.
![iRhythm logo](/files/LOGO/1388658-IRTC.png)
Company profile
Ticker
IRTC
Exchange
Website
CEO
Kevin King
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
IRhythm Technologies Inc
SEC CIK
Corporate docs
Subsidiaries
iRhythm Technologies Limited • iRhythm Singapore PTE. Ltd. • iRhythm Philippines, Inc. ...
IRTC stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
31 May 24
SD
Conflict minerals disclosure
29 May 24
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
First Quarter 2024 Financial Highlights
2 May 24
ARS
2023 FY
Annual report to shareholders
10 Apr 24
DEFA14A
Additional proxy soliciting materials
10 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
8-K
Entry into a Material Definitive Agreement
8 Mar 24
8-K
Irhythm Prices Upsized Offering of $575.0 Million of 1.50% Convertible Senior Notes Due 2029
5 Mar 24
8-K
Irhythm Announces Proposed Offering of $450.0 Million of Convertible Senior Notes
4 Mar 24
Transcripts
IRTC
Earnings call transcript
2024 Q1
2 May 24
IRTC
Earnings call transcript
2023 Q4
22 Feb 24
IRTC
Earnings call transcript
2023 Q3
2 Nov 23
IRTC
Earnings call transcript
2023 Q2
3 Aug 23
IRTC
Earnings call transcript
2023 Q2
3 Aug 23
IRTC
Earnings call transcript
2023 Q1
4 May 23
IRTC
Earnings call transcript
2022 Q4
23 Feb 23
IRTC
Earnings call transcript
2022 Q3
2 Nov 22
IRTC
Earnings call transcript
2022 Q2
6 Aug 22
IRTC
Earnings call transcript
2022 Q1
7 May 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 528.78 mm | 528.78 mm | 528.78 mm | 528.78 mm | 528.78 mm | 528.78 mm |
Cash burn (monthly) | (no burn) | (no burn) | 15.21 mm | 10.94 mm | 17.34 mm | 5.95 mm |
Cash used (since last report) | n/a | n/a | 58.81 mm | 42.30 mm | 67.05 mm | 23.00 mm |
Cash remaining | n/a | n/a | 469.97 mm | 486.48 mm | 461.73 mm | 505.78 mm |
Runway (months of cash) | n/a | n/a | 30.9 | 44.5 | 26.6 | 85.0 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 245 |
Opened positions | 105 |
Closed positions | 21 |
Increased positions | 49 |
Reduced positions | 63 |
13F shares | Current |
---|---|
Total value | 3.68 tn |
Total shares | 33.73 mm |
Total puts | 142.50 k |
Total calls | 226.30 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 2.95 mm | $342.14 bn |
Capital Research Global Investors | 2.50 mm | $289.46 bn |
BLK Blackrock | 2.44 mm | $283.17 bn |
Artisan Partners Limited Partnership | 2.14 mm | $248.81 bn |
Sands Capital Management | 2.14 mm | $248.59 bn |
MKFCF Mackenzie Financial | 1.35 mm | $156.40 bn |
Alliancebernstein | 1.23 mm | $143.25 bn |
JPM JPMorgan Chase & Co. | 963.26 k | $111.74 bn |
Holocene Advisors | 918.65 k | $106.56 bn |
Blair William & Co | 832.93 k | $96.62 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jul 24 | Minang Turakhia | Common Stock | Sell | Dispose S | No | No | 105.65 | 1,404 | 148.33 k | 27,255 |
3 Jun 24 | Sumi Shrishrimal | Common Stock | Sell | Dispose S | No | No | 88.91 | 1,131 | 100.56 k | 23,298 |
3 Jun 24 | Marc W. Rosenbaum | Common Stock | Sell | Dispose S | No | No | 88.91 | 510 | 45.34 k | 8,174 |
29 May 24 | Ling Karen | Common Stock | Grant | Acquire A | No | No | 0 | 1,841 | 0.00 | 8,210 |
29 May 24 | Brian B Yoor | Common Stock | Grant | Acquire A | No | No | 0 | 1,841 | 0.00 | 4,240 |
News
The Analyst Verdict: iRhythm Technologies In The Eyes Of 5 Experts
16 Jul 24
Truist Securities Maintains Buy on iRhythm Technologies, Lowers Price Target to $134
16 Jul 24
Morgan Stanley Maintains Overweight on iRhythm Technologies, Lowers Price Target to $130
15 Jul 24
This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
20 Jun 24
Wolfe Research Upgrades iRhythm Technologies to Outperform, Announces $115 Price Target
20 Jun 24
Press releases
iRhythm Technologies to Report Second Quarter 2024 Financial Results on August 1, 2024
18 Jul 24
iRhythm Technologies Achieves Significant Operational Milestone with Launch of Initial Phase of Manufacturing Automation
17 Jun 24
Investigation Alert Hut 8, Xponential Fitness, and iRhythm Technologies: Submit Your Information Now to Johnson Fistel, LLP
13 Jun 24
iRhythm Technologies to Present at the 2024 Truist Securities MedTech Conference
4 Jun 24
iRhythm Technologies to Present at the William Blair 44th Annual Growth Stock Conference
22 May 24